These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11313023)

  • 1. Adherence assessment to highly active antiretroviral therapy.
    Tsasis P
    AIDS Patient Care STDS; 2001 Mar; 15(3):109-15. PubMed ID: 11313023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adhering to antiretroviral therapies.
    Laurence J
    AIDS Patient Care STDS; 2001 Mar; 15(3):107-8. PubMed ID: 11313022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to HAART among patients with HIV: breakthroughs and barriers.
    Ickovics JR; Meade CS
    AIDS Care; 2002 Jun; 14(3):309-18. PubMed ID: 12042076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to HIV regimens: 10 vital lessons.
    Williams AB
    Am J Nurs; 2001 Jun; 101(6):37-43; quiz 44. PubMed ID: 11441760
    [No Abstract]   [Full Text] [Related]  

  • 5. Literacy, self-efficacy, and HIV medication adherence.
    Wolf MS; Davis TC; Osborn CY; Skripkauskas S; Bennett CL; Makoul G
    Patient Educ Couns; 2007 Feb; 65(2):253-60. PubMed ID: 17118617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taking HAART in the fight against HIV/AIDS.
    Jones SG
    Nurs Manage; 2002 May; 33(5):25-30. PubMed ID: 12006885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women.
    Cruess DG; Minor S; Antoni MH; Millon T
    J Pers Assess; 2007 Dec; 89(3):277-90. PubMed ID: 18001228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.
    Spire B; Duran S; Souville M; Leport C; Raffi F; Moatti JP;
    Soc Sci Med; 2002 May; 54(10):1481-96. PubMed ID: 12061483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of short-term success of antiretroviral therapy in HIV infection.
    Oette M; Kroidl A; Göbels K; Stabbert A; Menge M; Sagir A; Kuschak D; O'hanley T; Bode JG; Häussinger D
    J Antimicrob Chemother; 2006 Jul; 58(1):147-53. PubMed ID: 16687458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing efficacy and tolerability in today's HAART.
    Pozniak A
    AIDS Read; 2003 Sep; ():S4-8. PubMed ID: 14601553
    [No Abstract]   [Full Text] [Related]  

  • 12. Rate and predictors of self-chosen drug discontinuations in highly active antiretroviral therapy-treated HIV-positive individuals.
    Murri R; Guaraldi G; Lupoli P; Crisafulli R; Marcotullio S; von Schloesser F; Wu AW
    AIDS Patient Care STDS; 2009 Jan; 23(1):35-9. PubMed ID: 19183079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intention to adhere to HIV treatment: a patient-centred predictor of antiretroviral adherence.
    Nelsen A; Gupta S; Trautner BW; Petersen NJ; Garza A; Giordano TP; Naik AD; Rodriguez-Barradas MC
    HIV Med; 2013 Sep; 14(8):472-80. PubMed ID: 23551395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV meds: keeping trouble at bay.
    Daughtry LM; Bankston JB; Deshotels JM
    RN; 2002 Feb; 65(2):31-5; quiz 36. PubMed ID: 15328865
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors affecting patient adherence to highly active antiretroviral therapy.
    Escobar I; Campo M; Martín J; Fernández-Shaw C; Pulido F; Rubio R
    Ann Pharmacother; 2003 Jun; 37(6):775-81. PubMed ID: 12773060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana.
    Vriesendorp R; Cohen A; Kristanto P; Vrijens B; Rakesh P; Anand B; Iwebor HU; Stiekema J
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1115-21. PubMed ID: 17882408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges of adherence management in human immunodeficiency virus pharmacotherapy.
    Park-Wyllie LY; Phillips EJ
    Can J Clin Pharmacol; 2003; 10(4):189-95. PubMed ID: 14712324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting and monitoring antiretroviral adherence.
    Gross R
    LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study.
    Rathbun RC; Farmer KC; Stephens JR; Lockhart SM
    Clin Ther; 2005 Feb; 27(2):199-209. PubMed ID: 15811483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing baseline religious practices and beliefs to predict adherence to highly active antiretroviral therapy among HIV-infected persons.
    Vyas KJ; Limneos J; Qin H; Mathews WC
    AIDS Care; 2014; 26(8):983-7. PubMed ID: 24499276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.